BACKGROUND: Models of controlled human malaria infection (CHMI) initiated by mosquito bite have been widely used to assess efficacy of preerythrocytic vaccine candidates in small proof-of-concept phase 2a clinical trials. Efficacy testing of blood-stage malaria parasite vaccines, however, has generally relied on larger-scale phase 2b field trials in malaria-endemic populations. We report the use of a blood-stage P. falciparum CHMI model to assess blood-stage vaccine candidates, using their impact on the parasite multiplication rate (PMR) as the primary efficacy end point. METHODS: Fifteen healthy United Kingdom adult volunteers were vaccinated with FMP2.1, a protein vaccine that is based on the 3D7 clone sequence of apical membrane antigen 1 (AMA1) and formulated in Adjuvant System 01 (AS01). Twelve vaccinees and 15 infectivity controls subsequently underwent blood-stage CHMI. Parasitemia was monitored by quantitative real-time polymerase chain reaction (PCR) analysis, and PMR was modeled from these data. RESULTS: FMP2.1/AS01 elicited anti-AMA1 T-cell and serum antibody responses. Analysis of purified immunoglobulin G showed functional growth inhibitory activity against P. falciparum in vitro. There were no vaccine- or CHMI-related safety concerns. All volunteers developed blood-stage parasitemia, with no impact of the vaccine on PMR. CONCLUSIONS: FMP2.1/AS01 demonstrated no efficacy after blood-stage CHMI. However, the model induced highly reproducible infection in all volunteers and will accelerate proof-of-concept testing of future blood-stage vaccine candidates. CLINICAL TRIALS REGISTRATION: NCT02044198.
BACKGROUND: Models of controlled human malaria infection (CHMI) initiated by mosquito bite have been widely used to assess efficacy of preerythrocytic vaccine candidates in small proof-of-concept phase 2a clinical trials. Efficacy testing of blood-stage malaria parasite vaccines, however, has generally relied on larger-scale phase 2b field trials in malaria-endemic populations. We report the use of a blood-stage P. falciparum CHMI model to assess blood-stage vaccine candidates, using their impact on the parasite multiplication rate (PMR) as the primary efficacy end point. METHODS: Fifteen healthy United Kingdom adult volunteers were vaccinated with FMP2.1, a protein vaccine that is based on the 3D7 clone sequence of apical membrane antigen 1 (AMA1) and formulated in Adjuvant System 01 (AS01). Twelve vaccinees and 15 infectivity controls subsequently underwent blood-stage CHMI. Parasitemia was monitored by quantitative real-time polymerase chain reaction (PCR) analysis, and PMR was modeled from these data. RESULTS: FMP2.1/AS01 elicited anti-AMA1 T-cell and serum antibody responses. Analysis of purified immunoglobulin G showed functional growth inhibitory activity against P. falciparum in vitro. There were no vaccine- or CHMI-related safety concerns. All volunteers developed blood-stage parasitemia, with no impact of the vaccine on PMR. CONCLUSIONS: FMP2.1/AS01 demonstrated no efficacy after blood-stage CHMI. However, the model induced highly reproducible infection in all volunteers and will accelerate proof-of-concept testing of future blood-stage vaccine candidates. CLINICAL TRIALS REGISTRATION: NCT02044198.
Authors: Mark E Polhemus; Alan J Magill; James F Cummings; Kent E Kester; Chris F Ockenhouse; David E Lanar; Sheetij Dutta; Arnoldo Barbosa; Lorraine Soisson; Carter L Diggs; Sally A Robinson; John D Haynes; V Ann Stewart; Lisa A Ware; Clara Brando; Urszula Krzych; Robert A Bowden; Joe D Cohen; Marie-Claude Dubois; Opokua Ofori-Anyinam; Els De-Kock; W Ripley Ballou; D Gray Heppner Journal: Vaccine Date: 2007-03-26 Impact factor: 3.641
Authors: Kazutoyo Miura; Hong Zhou; Ababacar Diouf; Samuel E Moretz; Michael P Fay; Louis H Miller; Laura B Martin; Mark A Pierce; Ruth D Ellis; Gregory E D Mullen; Carole A Long Journal: Clin Vaccine Immunol Date: 2009-05-13
Authors: Frances Sanderson; Laura Andrews; Alexander D Douglas; Angela Hunt-Cooke; Philip Bejon; Adrian V S Hill Journal: Am J Trop Med Hyg Date: 2008-06 Impact factor: 2.345
Authors: Sheetij Dutta; JoAnn S Sullivan; Katharine K Grady; J David Haynes; Jack Komisar; Adrian H Batchelor; Lorraine Soisson; Carter L Diggs; D Gray Heppner; David E Lanar; William E Collins; John W Barnwell Journal: PLoS One Date: 2009-12-03 Impact factor: 3.240
Authors: A D Douglas; L Andrews; S J Draper; K Bojang; P Milligan; S C Gilbert; E B Imoukhuede; A V S Hill Journal: J Infect Dis Date: 2011-05-01 Impact factor: 5.226
Authors: Susanne H Sheehy; Alexandra J Spencer; Alexander D Douglas; B Kim Lee Sim; Rhea J Longley; Nick J Edwards; Ian D Poulton; Domtila Kimani; Andrew R Williams; Nicholas A Anagnostou; Rachel Roberts; Simon Kerridge; Merryn Voysey; Eric R James; Peter F Billingsley; Anusha Gunasekera; Alison M Lawrie; Stephen L Hoffman; Adrian V S Hill Journal: PLoS One Date: 2013-06-18 Impact factor: 3.240
Authors: Michelle J Boyle; Linda Reiling; Gaoqian Feng; Christine Langer; Faith H Osier; Harvey Aspeling-Jones; Yik Sheng Cheng; Janine Stubbs; Kevin K A Tetteh; David J Conway; James S McCarthy; Ivo Muller; Kevin Marsh; Robin F Anders; James G Beeson Journal: Immunity Date: 2015-03-17 Impact factor: 31.745
Authors: David Llewellyn; Kazutoyo Miura; Michael P Fay; Andrew R Williams; Linda M Murungi; Jianguo Shi; Susanne H Hodgson; Alexander D Douglas; Faith H Osier; Rick M Fairhurst; Mahamadou Diakite; Richard J Pleass; Carole A Long; Simon J Draper Journal: Sci Rep Date: 2015-09-16 Impact factor: 4.379
Authors: Jean Claude Dejon-Agobe; Ulysse Ateba-Ngoa; Albert Lalremruata; Andreas Homoet; Julie Engelhorn; Odilon Paterne Nouatin; Jean Ronald Edoa; José F Fernandes; Meral Esen; Yoanne Darelle Mouwenda; Eunice M Betouke Ongwe; Marguerite Massinga-Loembe; Stephen L Hoffman; B Kim Lee Sim; Michael Theisen; Peter G Kremsner; Ayôla A Adegnika; Bertrand Lell; Benjamin Mordmüller Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Ruth O Payne; Sarah E Silk; Sean C Elias; Kazutoyo Miura; Ababacar Diouf; Francis Galaway; Hans de Graaf; Nathan J Brendish; Ian D Poulton; Oliver J Griffiths; Nick J Edwards; Jing Jin; Geneviève M Labbé; Daniel Gw Alanine; Loredana Siani; Stefania Di Marco; Rachel Roberts; Nicky Green; Eleanor Berrie; Andrew S Ishizuka; Carolyn M Nielsen; Martino Bardelli; Frederica D Partey; Michael F Ofori; Lea Barfod; Juliana Wambua; Linda M Murungi; Faith H Osier; Sumi Biswas; James S McCarthy; Angela M Minassian; Rebecca Ashfield; Nicola K Viebig; Fay L Nugent; Alexander D Douglas; Johan Vekemans; Gavin J Wright; Saul N Faust; Adrian Vs Hill; Carole A Long; Alison M Lawrie; Simon J Draper Journal: JCI Insight Date: 2017-11-02
Authors: Kathryn Milne; Alasdair Ivens; Adam J Reid; J Alexandra Rowe; Philip J Spence; Magda E Lotkowska; Aine O'Toole; Geetha Sankaranarayanan; Diana Munoz Sandoval; Wiebke Nahrendorf; Clement Regnault; Nick J Edwards; Sarah E Silk; Ruth O Payne; Angela M Minassian; Navin Venkatraman; Mandy J Sanders; Adrian Vs Hill; Michael Barrett; Matthew Berriman; Simon J Draper Journal: Elife Date: 2021-03-02 Impact factor: 8.140
Authors: Angela M Minassian; Sarah E Silk; Jordan R Barrett; Carolyn M Nielsen; Kazutoyo Miura; Ababacar Diouf; Carolin Loos; Jonathan K Fallon; Ashlin R Michell; Michael T White; Nick J Edwards; Ian D Poulton; Celia H Mitton; Ruth O Payne; Michael Marks; Hector Maxwell-Scott; Antonio Querol-Rubiera; Karen Bisnauthsing; Rahul Batra; Tatiana Ogrina; Nathan J Brendish; Yrene Themistocleous; Thomas A Rawlinson; Katherine J Ellis; Doris Quinkert; Megan Baker; Raquel Lopez Ramon; Fernando Ramos Lopez; Lea Barfod; Pedro M Folegatti; Daniel Silman; Mehreen Datoo; Iona J Taylor; Jing Jin; David Pulido; Alexander D Douglas; Willem A de Jongh; Robert Smith; Eleanor Berrie; Amy R Noe; Carter L Diggs; Lorraine A Soisson; Rebecca Ashfield; Saul N Faust; Anna L Goodman; Alison M Lawrie; Fay L Nugent; Galit Alter; Carole A Long; Simon J Draper Journal: Med (N Y) Date: 2021-06-11